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Background: The nuclear receptor liver X receptor (LXR) has two isoforms: LXRα and LXRβ. LXR activation
promotes cholesterol efflux in macrophages, but the relative importance of each LXR isoform in mediating
cholesterol efflux remains elusive.
Methods: We evaluated the ability of different doses of LXRs agonist T0901317 to affect cholesterol efflux in
human macrophages and its relationship with mRNA and protein levels of several well-characterized proteins
involved in cholesterol efflux, including ABCA1, ABCG1, SR-BI, LXRβ and LXRα, using quantitative real-time PCR,
Western blotting, and siRNA techniques.
Results: Here we show that LXRα rather than LXRβ sustains baseline cholesterol efflux in human blood-derived
macrophages. Treatment of human macrophages with a non-isoform-specific LXR agonist T0901317 substantially
increased HDL- and apoA-I-mediated cholesterol efflux, which was associated with increased mRNA and protein
expression levels of ABCA1, ABCG1, SR-BI, LXRα and LXRβ. The siRNA- mediated silencing of LXRα, but not LXRβ
significantly reduced the protein levels of ABCA1,ABCG1, and SR-BI as wellas HDL- and ApoA1-mediated cholesterol
in human macrophages.
Conclusions: These findings imply that LXRα- rather than LXRβ- specific agonists may promote reverse cholesterol
transport in humans.
Keywords: Reverse cholesterol transport, Liver X receptor, siRNA, ABC transporter, AtherosclerosisBackground
Atherosclerosis is characterized by the presence of cho-
lesterol-laden macrophages (foam cells) within the arterial
wall [1,2]. The formation of foam cells is a result of dis-
rupted balance between cholesterol uptake and efflux in
macrophages. Macrophage cholesterol efflux is predo-
minantly mediated by ATP-binding cassette (ABC) trans-
porters A1 (ABCA1), ABCG1, and scavenger receptor
class B type I (SR-BI) [3]. It is the initial step of reverse
cholesterol transport (RCT), a process that removes excess
cholesterol from peripheral tissues/cells including macro-
phages to circulating high density lipoproteins (HDLs) for
fecal disposal via the hepatobiliary route [4]. Liver X re-
ceptors (LXRs) are nuclear receptors that function as
cholesterol sensors and regulate transcription of a set of* Correspondence: zysong2010@126.com; zhangq931@126.com
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unless otherwise stated.genes associated with cholesterol absorption, transport,
efflux and excretion, thus playing a pivotal role in choles-
terol homeostasis in vivo [5]. There are two LXR isoforms,
LXRα and LXRβ. Each of them forms a heterodimer with
a retinoid X receptor (RXR) to activate target gene ex-
pression by 3 binding to LXR response elements (LXREs)
located in the promoter 3 regions of the target genes [6].
LXRα and LXRβ are similar in structure, ligand-binding
domains (LBDs), and DNA-binding domains (DBDs), but
their nuclear retention and localization as well as func-
tions display some differences [7]. The two isoforms may
have evolved from one ancestor. Pufferfish has only one
LXRα, which is more closely related to mammalian LXR
genes by sequence similarity, yet the pattern of tissue
expression more closely resembles mammalian LXRβ
genes in its ubiquity of expression [8]. The sequence data
suggests that the two LXR isoforms are likely duplicated
from a single ancestor LXR gene, and this duplication
is concurrent with the evolution of mammals [9]. In. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pose tissue, small intestine, kidneys and macrophages,
whereas the LXRβ isoform is ubiquitously expressed [10].
T0901317 is a general agonist for both LXR isoforms
[11]. It has been shown that the activation of LXRs by
T0901317 facilitates cholesterol efflux in macrophages and
inhibits atherosclerosis in animal models [12,13]. However,
the relative importance of each LXR isoform in mediating
cholesterol efflux in human macrophages remains elusive.
In this study, we demonstrate that the baseline cholesterol
efflux in human blood-derived macrophages depends on
LXRα, but not LXRβ, implying a potential role of LXRα-




LXRs agonist T0901317 was from Sigma, USA. Total RNA
extraction reagent RNAiso Plus, PrimeScript RT reagent
kit, and SYBR-Green PCR kit were obtained from Takara
(Japan). Immunoblot reagents were purchased from the
Beyotime Institute of Biotechnology (China). LXRα siRNA
and LXRβ siRNA were synthesized by Shanghai Genechem
(Shanghai, China). All other chemicals were of the best
grade available from commercial sources.
Cell culture
Human peripheral blood monocytes were isolated from
blood samples of 3 healthy volunteers using Ficoll/Hypaque
gradient centrifugation. The pooled monocytes were
incubated in DMEM supplemented with 10% autologous
serum for 10 days so that they would differentiate into
macrophages. Written informed consent was obtained
from all subjects for participation in the study, and the
protocol was approved by the ethics committee of South-
west Hospital.
Cellular cholesterol efflux assays
Human macrophages were cultured as indicated above.
Macrophages were then labeled with [3H]-cholesterol
(0.3 μCi/mL) in serum-free DMEM containing 50 μg/mL
ox-LDL and 0.2% bovine serum albumin (BSA) for 24 h.
The cells were washed twice with phosphate-buffered
saline (PBS) and incubated in 25 mL of DMEM containing
0.2% BSA with or without LXRs agonist T0901317 at 5 or
10 μmol/L for 48 h. The media were then replaced with
DMEM containing 0.2% BSA in the presence of lipid-free
apoA-I (10 μg/mL) or HDL (50 μg/mL) for 24 h. Efflux
media were collected and centrifuged to remove floating
cells. Monolayer cells were washed twice with PBS, and
cellular lipids were extracted using isopropanol. The radio-
activity in media and cell-associated [3H]-cholesterol was
then measured using a liquid scintillation counter. The per-
cent efflux was calculated with the following equation:[total medium counts/ (total cellular counts + total medium
counts)] × 100%.
RNA isolation and quantitative realtime PCR analysis
Total RNAs were extracted using RNAiso Plus reagents ac-
cording to manufacturer’s instructions. PCR primers were
synthesized by Shanghai Sangon (Shanghai, China) and the
primer sequences used were as follows: ABCA1: forward
primer: 5’-AAG CCA AGC ATC TTC AGT TC-3’, reverse
primer: 5’-CCA TAC AGC AAG AGC AGA AGG-3’;
ABCG1: forward primer: 5’-ATA CAG GGG AAA GGT
CTC CAA T-3’, reverse primer: 5’-CCC CCG AGG TCT
CTC TTA TAG T-3’; SR-BI: forward primer: 5’-AGG GAT
AGG GTT GGA GTC AGC-3’, reverse primer: 5’-CGT
TGT AAT GGA AGC CAG AGG-3’; LXRα: forward pri-
mer: 5’-AGG CCG GTG CTG AGT ATG TC-3’, reverse
primer: 5’-GGG CTC CATAAA GTC ACC AA −3’; LXRβ:
forward primer: 5’-TGT CGT GTG CTC AGT ATG TG-3’,
reverse primer: 5’-AGC CGC CAT ATA GTC ACT GT-3’;
and GAPDH: forward primer: 5’-AGG CCG GTG CTG
AGT ATG TC-3’, reverse primer: 5’-TGC CTG CTT CAC
CAC CTT CT-3’. Real-time quantitative PCR was per-
formed with SYBR® Premix Ex Taq™ II on a Bio-Rad Light-
Cycler with an iQ3.1 realtime PCR system. Melt curve
analysis of all real-time PCR products was used to produce
a single DNA duplex. Quantitative measurements were
obtained using the ΔΔCt method. GAPDH was used as an
invariant internal control.
Western blot analysis
Cells were harvested and protein extracts prepared in ac-
cordance with the manufacturer’s instructions. Immunoblot
analysis [12% SDS-PAGE; 30 μg proteins per lane] was then
performed using rabbit anti-ABCA1, anti-ABCG1, anti-SR-
BI, anti- LXRα, anti-LXRβ and anti-GAPDH antibodies
(Abcam, USA). Proteins were visualized using Enhanced
Chemiluminescence.
Screening for effective LXR siRNA fragments
SiRNAs specific for human LXRα and LXRβ and the nonsi-
lencing (control) siRNAs were synthesized by Shanghai
Genechem (Shanghai, China). Human macrophages (1 ×
10^6 cells/well) were transfected with each siRNA using
Lipofectamine2000 (Invitrogen). Following 48 h transfec-
tion, the second siRNA fragment (5’-AAC TCA ATG ATG
CTG AGT T-3’, LXRα-siRNA) targeting LXRα suppressed
LXRα expression by 70%, and the third siRNA fragment
(5’-ATG TCA CTG ATT CTG AGT AA-3’, LXRβ- siRNA)
targeting LXRβ suppressed LXRβ expression by 75% ac-
cording to realtime PCR results.
LXR siRNA transfection and Western blot analysis
Human macrophages were grown in culture flasks at a
density of 1 × 10^7/mL for 12 h, washed twice with PBS,
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human serum. The non-targeting control siRNA, LXRα
siRNA and LXRβ siRNA were added to the culture flasks
separately, and cultured for 96 h. Cells were then harvested
and protein extracts prepared in accordance with the ma-
nufacturer’s instructions. The proteins were then subjected
to immunoblot analysis [12% SDS-PAGE; 60 μg protein per
lane] using a rabbit anti-ABCA1, anti-ABCG1, anti-SR-BI,
anti- LXRα, anti-LXRβ or anti-GAPDH (Abcam, USA)-spe-
cific antibody. Proteins were visualized using Enhanced
Chemiluminescence reagents.Cholesterol efflux assays
Human macrophages were cultured as indicated above.
Human macrophages were then labeled with [3H]-cho-
lesterol (0.3 μCi/mL) in serum-free DMEM containing
50 μg/mL ox-LDL and 0.2% BSA for 24 h. The cells were
washed twice with PBS, cultured in DMEM containing
0.2% BSA, then treated with siRNAs as described above.
Seventy-two hours post-siRNA treatment, the media were
replaced with DMEM containing 0.2% BSA and lipid-free
apoA-I (10 μg/mL) or HDL (50 μg/mL) for cholesterol
efflux assays as described above.Statistical analysis
Data are expressed as Mean ± Standard Error of the Mean
(SEM). Results were analyzed using one-way ANOVA with
SPSS 13.0 software. P < 0.05 was considered statistically
significant.Figure 1 LXRs agonist T0901317 enhances cholesterol efflux from hu
human macrophages were treated with T0901317 or the vehicle for 48 h. C
HDL- (B) mediated cholesterol efflux as described under the Methods. Data
as Mean ± SEM, *P < 0.05 (vs control).Results
LXRs agonist T0901317 enhances cholesterol efflux in
human macrophages
To determine if LXRs agonist T0901317 promotes cho-
lesterol efflux in human blood-derived macrophages, we
measured HDL- and apoAI-mediated cholesterol efflux in
these macrophages. At 5 and 10 μmol/L, T0901317 sig-
nificantly increased HDL-mediated cholesterol efflux by
36% (from 30.3% to 41.2%) and 50% (from 30.3% to 45.6%)
(Figure 1A) as well as apoA-I-mediated cholesterol efflux
by 115% 9 (from 2.6% to 5.6%) and 165% (from 2.6% to
6.9%) (Figure 1B), respectively.
LXRs agonist T0901317 increases mRNA and protein
expression levels of genes involved in cholesterol efflux
in human macrophages
ABCA1 and ABCG1 are LXR target genes critically in-
volved in cholesterol efflux [14]. As expected, LXRs agonist
T0901317 treatment increased mRNA levels of ABCA1
and ABCG1 by 550% and 605% respectively at 5 μmol/L,
and 780% and 945% respectively at 10 μmol/L in human
macrophages (Figure 2A). The mRNA levels of SR-BI,
LXRα and LXRβ were also elevated significantly by 255%,
560%, and 365%, respectively, at 5 μmol/L, and by 470%,
895% and 515%, respectively, at 10 μmol/L. Similar changes
were found for the protein levels of these genes (Figure 2B,
2C and 2D). In human macrophages, T0901317 treatment
increased the protein expression levels of ABCA1, ABCG1,
SR-B1, LXRα and LXRβ by 295%, 309%, 355%, 550%, and
485%, respectively, at 5 μmol/L, and by 560%, 490%, 520%,
740%, and 690%, respectively.man macrophages. Following 24 h of labeling with [3H]-cholesterol,
ells were then washed with PBS, and assayed for apoA-I- (A) or
in each group were obtained from triplicate flasks. Data are presented
Figure 2 LXR agonist T901317 increases expression of genes related to cholesterol efflux. Human macrophages were treated without or
with LXRs agonist T0901317 at 5 μmol/L or 10 μmol/L for 24 h, and ABCA1, ABCG1, SR-BI, LXRα and LXRβ mRNA expression levels were measured
by real-time quantitative PCR (A). Human macrophages were treated without or with LXRs agonist T0901317 at 5 μmol/L or 10 μmol/L for 48 h,
and ABCA1, ABCG1, SR-BI, LXRα and LXRβ protein expression levels were measured by immunoblotting (B, C and D). Similar results were obtained in
three independent experiments. Data are presented as Mean ± SEM, *P < 0.05 (vs control).
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ABCA1, ABCG1 and SR-BI expression in human
macrophages
To determine the relative importance of each LXR isoform
in maintaining baseline levels of ABCA1, ABCG1 and
SR-BI expression in human macrophages, we indepen-
dently silenced each LXR isoform in these cells. Silencing
of LXRα (~79% efficiency) in human macrophages re-
duced the protein expression levels of ABCA1, ABCG1,
and SR-BI to 21.7%, 24.4%, and 28.2% of each non-targetin
control siRNA group, respectively, without affecting the
protein expression of LXRβ. However, when LXRβ expres-
sion was silenced by ~78% in human macrophages, the
protein expression levels of ABCA1, ABCG1, and SR-BI
were not affected (Figure 3A, 3B and 3C).
LXRα rather than LXRβ sustains the baseline cholesterol
efflux in human macrophages
To determine the relative contribution of each LXR iso-
form to baseline levels of cholesterol efflux in human mac-
rophages, we independently silenced each LXR isoform by
the siRNA approach and measured HDL- and apoA-
I-mediated cholesterol efflux in these cells (Figure 4A
and 4B). LXRα siRNA treatment significantly reduced
HDL-, and apoA-I- dependent cholesterol efflux by ~48%
(from 33% to 17.2%) and ~69% (from 3.1% to 0.95%),
respectively, in human macrophages. However, theseeffects were not observed in human macrophages treated
with LXRβ siRNA.
Discussion
The major finding of this study is that LXRα rather than
LXRβ expression is required for sustaining the baseline
protein expression levels of ABCA1, ABCG1 and SR-BI,
as well as HDL- and apoA-I- mediated cholesterol efflux
in human blood-derived macrophages. There has been in-
creasing interest in developing LXR agonists to promote
cholesterol efflux and subsequent reverse cholesterol
transport. LXRα activation was shown to promote choles-
terol efflux and reverse cholesterol transport [15], making
LXRs as attractive drug targets. However, simultaneous
activation of both LXRα and LXRβ by a synthetic agonist
T0901317 induces hepatic steatosis [16], an unwanted side
effect. It was speculated that compounds activating LXRα
in a tissue-specific manner or specifically targeting LXRα
might be useful. Results from subsequent animal studies
are in agreement with this speculation [17,18]. Our results
demonstrate that the role of LXRα in mediating choles-
terol efflux in human macrophages is minimal. While de-
veloping LXR agonists for use in humans, we may need to
focus on agonists specifically targeting LXRα isoform. Our
data are consistent with previous findings showing that
LXRs agonist T0901317 increases expression of ABCA1
and ABCG1 to mediate cholesterol efflux in macrophages
Figure 3 The baseline protein expression levels of ABCA1, ABCG1 and SR-BI depend on LXRα, but not LXRβ in human macrophages.
Human macrophages were transfected with non-targeting control, LXRα siRNA, or LXRβ siRNA, and then incubated for 96 h. ABCA1, ABCG1, SR-BI,
LXRα and LXRβ protein expression levels were measured by immunoblotting (A, B and C). Similar results were obtained in three independent
experiments. Data are presented as Mean ± SEM, *P < 0.05 (vs non-targeting control).
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Here we found that T0901317 increases SR-BI mRNA and
protein levels in human blood-derived macrophages. It is
currently unclear how LXRs agonist T0901317 regulates
SR-BI mRNA and protein expression. Nonetheless, in-
creased SR-BI expression has the potential to increase the
bidirectional cholesterol transport, thus unlikely contri-
buting to increased cholesterol efflux in T0901317-treatedFigure 4 The baseline levels of cholesterol efflux depend on LXRα, but
for 24 h, human macrophages were transfected with non-targeting contro
for 72 h. The media were then replaced with DMEM containing 0.2% BSA i
24 h, a ssayed for cholesterol efflux in triplicate as described under the Me
control).human macrophages. The relative importance of each
LXR isoform in sustaining baseline expression levels of
ABCA1 and ABCG1 as well as cholesterol efflux was un-
clear in human macrophages. In this study, we found that
LXRα isoform is essential and LXRβ is dispensable for
maintaining baseline ABCA1 and ABCG1 expression and
cholesterol efflux in human blood-derived macrophages.
During the preparation of this manuscript, a study withnot LXRβ. in human macrophages. After labeled with [3H]-cholesterol
l, LXRα , or LXRβ siRNA, and incubated in DMEM containing 0.2% BSA
n the presence of apoA-I (10 μg/mL) (A) or HDL (50 μg/mL) (B) for
thods. Data are presented as Mean ± SEM, *P < 0.05 (vs non-targeting
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our finding is a reproducible phenomenon in human mac-
rophages. The two studies collectively warrant detailed
molecular studies of this reproducible observation in the
future.
Conclusion
In conclusions, LXRα rather than LXRβ plays a predo-
minant role in mediating cholesterol efflux in human
macrophages.
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